Obesity potentially reduces fertility, but systematic reviews are lacking to summarize the existing literature. Therefore, we systematically summarized the association between preconception body mass ...

Sacituzumab govitecan was approved for the treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer. Hope S Rugo and colleagues have completed the TROPiCS-02 trial to evaluate the effect and safety of sacituzumab govitecan treatment.1 A Comment discusses whether these results are clinically meaningful.2 Further to the trial, the safety issues deserve greater discussion. Compared with chemotherapy, the incidence of treatment-emergent adverse events from sacituzumab govitecan use is higher,1 in keeping with sacituzumab govitecan's known safety profile.

Recently, in the TROPiCS-02 study,1 it was reported that sacituzumab govitecan showed statistically and clinically significant overall survival benefits in patients with endocrine-resistant hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer. Furthermore, the Article uses the phrase “manageable safety profile” to describe the safety data, underscoring the drug's safety.